These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16583343)

  • 1. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
    Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial.
    Brener SJ; Barr LA; Burchenal JE; Wolski KE; Effron MB; Topol EJ
    Am J Cardiol; 1999 Sep; 84(6):728-30, A8. PubMed ID: 10498145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
    Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
    Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
    Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The initial experience of the use of ReoPro in high-risk coronary angioplasty in Italy: the Italian Registry on the Conditions for the Use of ReoPro during Angioplasty (R.I.CO.R.D.A.)].
    Simonetti I; Gallopin M; Klugmann S; Gensini GF
    Ital Heart J Suppl; 2000 Jan; 1(1):88-96. PubMed ID: 10832124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Leoncini M; Toso A; Dabizzi RP
    Int J Cardiol; 2006 Mar; 108(1):36-42. PubMed ID: 15927285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
    Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
    J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
    Sundlof DW; Rerkpattanapitat P; Wongpraparut N; Pathi P; Kotler MN; Jacobs LE; Ledley GS; Yazdanfar S
    Am J Cardiol; 1999 Jun; 83(11):1569-71, A7. PubMed ID: 10363875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
    Kereiakes DJ; Broderick TM; Abbottsmith C; Shimshak TM
    J Invasive Cardiol; 2000 Feb; 12(2):95-8. PubMed ID: 10731271
    [No Abstract]   [Full Text] [Related]  

  • 18. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty.
    Lee CW; Moon DH; Hong MK; Lee JH; Choi Si; Yang HS; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2002 Dec; 90(11):1243-6. PubMed ID: 12450607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.